162 related articles for article (PubMed ID: 36090479)
1.
Bhojnagarwala PS; O'Connell RP; Park D; Liaw K; Ali AR; Bordoloi D; Cassel J; Tursi NJ; Gary E; Weiner DB
Mol Ther Oncolytics; 2022 Sep; 26():289-301. PubMed ID: 36090479
[TBL] [Abstract][Full Text] [Related]
2. Multivalent
Park DH; Liaw K; Bhojnagarwala P; Zhu X; Choi J; Ali AR; Bordoloi D; Gary EN; O'Connell RP; Kulkarni A; Guimet D; Smith T; Perales-Puchalt A; Patel A; Weiner DB
Mol Ther Oncolytics; 2023 Mar; 28():249-263. PubMed ID: 36915911
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
4. An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts.
Pandya H; Gibo DM; Garg S; Kridel S; Debinski W
Neuro Oncol; 2012 Jan; 14(1):6-18. PubMed ID: 21946118
[TBL] [Abstract][Full Text] [Related]
5. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.
Hegde M; Corder A; Chow KK; Mukherjee M; Ashoori A; Kew Y; Zhang YJ; Baskin DS; Merchant FA; Brawley VS; Byrd TT; Krebs S; Wu MF; Liu H; Heslop HE; Gottschalk S; Yvon E; Ahmed N
Mol Ther; 2013 Nov; 21(11):2087-101. PubMed ID: 23939024
[TBL] [Abstract][Full Text] [Related]
6. Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme.
Lazovic J; Jensen MC; Ferkassian E; Aguilar B; Raubitschek A; Jacobs RE
Clin Cancer Res; 2008 Jun; 14(12):3832-9. PubMed ID: 18559603
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel role of IL-13Rα2 in human Glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway.
Bhardwaj R; Suzuki A; Leland P; Joshi BH; Puri RK
J Transl Med; 2018 Dec; 16(1):369. PubMed ID: 30572904
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy.
Knudson KM; Hwang S; McCann MS; Joshi BH; Husain SR; Puri RK
Front Immunol; 2022; 13():878365. PubMed ID: 35464460
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models.
Nakashima H; Fujisawa T; Husain SR; Puri RK
J Transl Med; 2010 Nov; 8():116. PubMed ID: 21067607
[TBL] [Abstract][Full Text] [Related]
10. Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma.
Gardell JL; Matsumoto LR; Chinn H; DeGolier KR; Kreuser SA; Prieskorn B; Balcaitis S; Davis A; Ellenbogen RG; Crane CA
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33122397
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas.
Yin Y; Boesteanu AC; Binder ZA; Xu C; Reid RA; Rodriguez JL; Cook DR; Thokala R; Blouch K; McGettigan-Croce B; Zhang L; Konradt C; Cogdill AP; Panjwani MK; Jiang S; Migliorini D; Dahmane N; Posey AD; June CH; Mason NJ; Lin Z; O'Rourke DM; Johnson LA
Mol Ther Oncolytics; 2018 Dec; 11():20-38. PubMed ID: 30306125
[TBL] [Abstract][Full Text] [Related]
12. Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous signaling.
Hsi LC; Kundu S; Palomo J; Xu B; Ficco R; Vogelbaum MA; Cathcart MK
Mol Cancer Ther; 2011 Jul; 10(7):1149-60. PubMed ID: 21596889
[TBL] [Abstract][Full Text] [Related]
13. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.
Kioi M; Seetharam S; Puri RK
Mol Cancer Ther; 2008 Jun; 7(6):1579-87. PubMed ID: 18566228
[TBL] [Abstract][Full Text] [Related]
14. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy.
Saikali S; Avril T; Collet B; Hamlat A; Bansard JY; Drenou B; Guegan Y; Quillien V
J Neurooncol; 2007 Jan; 81(2):139-48. PubMed ID: 17004103
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain.
Kawakami K; Terabe M; Kawakami M; Berzofsky JA; Puri RK
Cancer Res; 2006 Apr; 66(8):4434-42. PubMed ID: 16618770
[TBL] [Abstract][Full Text] [Related]
16. IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma.
Rechberger JS; Porath KA; Zhang L; Nesvick CL; Schrecengost RS; Sarkaria JN; Daniels DJ
Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631512
[TBL] [Abstract][Full Text] [Related]
17. Molecular cloning of the rat IL-13 alpha 2 receptor cDNA and its expression in rat tissues.
Wu AH; Low WC
J Neurooncol; 2002 Sep; 59(2):99-105. PubMed ID: 12241113
[TBL] [Abstract][Full Text] [Related]
18. Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer.
Fujisawa T; Joshi BH; Puri RK
J Transl Med; 2011 Apr; 9():37. PubMed ID: 21477288
[TBL] [Abstract][Full Text] [Related]
19. Killing effect of interleukin-13 receptor alpha 2 (IL-13Ralpha2) sensitized DC-CTL cells on human glioblastoma U251 cells.
Yan X; Su Z; Zhang J; Wu Z; Ye S; Lu X; Wu J; Zeng Y; Zheng W
Cell Immunol; 2010; 263(2):172-5. PubMed ID: 20400066
[TBL] [Abstract][Full Text] [Related]
20. A novel interleukin-13 receptor alpha 2-targeted hybrid peptide for effective glioblastoma therapy.
Kurihara R; Horibe T; Shimizu E; Torisawa A; Gaowa A; Kohno M; Kawakami K
Chem Biol Drug Des; 2019 Jul; 94(1):1402-1413. PubMed ID: 30903640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
